Prevention of Progression of Prediabetes, Obesity and CV Risk
NCT06446531
Recruiting
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Pre-Diabetes, Weight, Body, Cardiovascular Diseases
Register for Updates
Latino Semaglutide Study
NCT05087342
Completed
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/09/2024
Locations: Loma Linda University Health, Loma Linda, California
Conditions: Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
Register for Updates
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
NCT06445075
Active Not Recruiting
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/01/2024
Locations: ProSciento CRU, Chula Vista, California +6 locations
Conditions: Overweight and Obesity
Register for Updates
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist
NCT06500429
Completed
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg BID) or placebo for 5 days beginning on Day 1. On Day 2, all participants will receive a single subcutaneous injection of a GLP-1 agonist (semaglutide). Participants will remain at the clinical research unit for the duration of the treatment period. The goal of this clinical trial is to evaluate the safety and efficacy of NG101 compared to placebo, when also administered along with a... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/23/2024
Locations: Celerion, Tempe, Arizona
Conditions: Overweight and Obesity, Healthy
Register for Updates
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
NCT04969939
Completed
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: Diablo Clinical Research, Inc., Walnut Creek, California +13 locations
Conditions: Obesity
Register for Updates
Semaglutide Use in Elderly Obese Patients
NCT05302596
Active Not Recruiting
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/27/2024
Locations: Diabetes and Endocrinology Research Center, Buffalo, New York
Conditions: Obesity, Aging
Register for Updates
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
NCT06282458
Active Not Recruiting
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Gender:
ALL
Ages:
Between 60 years and 100 years
Trial Updated:
08/08/2024
Locations: Pinnacle Trials, Anniston, Alabama +13 locations
Conditions: Muscle Loss, Obesity
Register for Updates
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
Completed
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/06/2024
Locations: Central Alabama Research, Birmingham, Alabama +832 locations
Conditions: Overweight, Obesity
Register for Updates
Mechanisms of Semaglutide Therapy in Heart Failure Patients
NCT06541509
Recruiting
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which remain poorly defined. In large clinical trials, semaglutide improved the outcomes in obese patients, patie... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
08/05/2024
Locations: Greenstone Biosciences, Palo Alto, California +2 locations
Conditions: Heart Failure, Obesity
Register for Updates
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
NCT05579977
Terminated
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Ry... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/09/2024
Locations: Trinity Clinical Research, Centreville, Alabama +89 locations
Conditions: Diabetes Mellitus, Obesity
Register for Updates
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
NCT05035095
Completed
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets ('dummy' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation. Sem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +50 locations
Conditions: Obesity, Overweight
Register for Updates
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898
Recruiting
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: 1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated fir... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/20/2024
Locations: Amish Research Clinic, Lancaster, Pennsylvania
Conditions: Obesity, Diabetes Type 2
Register for Updates